Adjunctive esketamine appears effective for patients with major depressive disorder (MDD) who are treatment-resistant or suicidal, a meta-analysis published in The Journal of Clinical Psychiatry concluded.
A novel vasopressin 1B (V1B) receptor antagonist eased depressive symptoms when used as an adjunctive treatment in patients with major depressive disorder (MDD) in a small phase 2 study in the Journal of Psychiatric Research.
Depression is “vastly underdiagnosed” in people with human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS), states a literature review published online in the Harvard Review of Psychiatry.
The protein GPR56 may provide an easy-to-measure biomarker of a patient’s response to antidepressants as well as a novel drug target for the treatment of major depressive disorder, according to a published study.
An interactive voice application’s assessment of patient well-being through analysis of their speech was highly comparable with physicians’ tracking of patient well-being, according to a study published online in PLOS One.
Resting-state electroencephalographic (EEG) data may help in predicting the outcome of escitalopram treatment in patients with major depressive disorder (MDD), suggests a study published online in JAMA Network Open.
Stay in the know. Psychiatry and Behavioral Health Learning Network Newsletter